M.M.A. TECH LTD

Their core work

M.M.A. TECH LTD is an Israeli medtech SME developing advanced biocompatible polymer materials specifically engineered for trauma implants used in orthopaedic surgery. Their core work centers on creating a next-generation implant material that can replace conventional metal hardware (such as plates and screws used in open reduction internal fixation procedures) with biocompatible alternatives that reduce complications and revision surgeries. They progressed from feasibility through full product development under the EU SME Instrument, suggesting they own proprietary material formulations rather than acting as a service provider. Their focus is deep and narrow: one technology, one clinical application, pursued through a full innovation cycle.

What they specialise in

How they've shifted over time

M.M.A. TECH LTD has a compressed but clear trajectory: their 2016 Phase 1 project produced no indexable keywords, consistent with an early-stage feasibility study where the technology was still being scoped. By 2017, the Phase 2 project crystallised around a specific cluster — implant, trauma, biocompatible polymer, advanced materials, orthopaedics — showing that the concept had hardened into a concrete product development programme. There is no observable shift in domain; rather, the evolution is one of depth: from concept validation to full-scale development of the same core technology.

M.M.A. TECH LTD is on a classic SME product development path — having completed Phase 2 funding through 2021, they are likely in late-stage validation, regulatory preparation, or early commercialisation of their polymer implant material, making them most relevant to partners in medtech manufacturing, clinical validation, or orthopaedic distribution.

How they like to work

M.M.A. TECH LTD has acted exclusively as project coordinator and appears to have pursued both EU grants as a single-company applicant — the SME Instrument was specifically designed for this model. They show no recorded consortium partners across either project, which is typical of IP-protective deep-tech SMEs that treat EU funding as R&D capital rather than a networking vehicle. Working with them likely means engaging directly with the founding team, with minimal bureaucratic overhead but also no pre-existing partner network to tap into.

M.M.A. TECH LTD has zero recorded consortium partners across its two H2020 projects, both structured as single-entity SME Instrument grants. Their collaboration footprint within the EU programme is effectively non-existent, which reflects the nature of the SME Instrument rather than isolation — but it means they bring no pre-built European partner network.

What sets them apart

M.M.A. TECH LTD is one of the few Israeli SMEs in the H2020 programme to have successfully secured both Phase 1 and Phase 2 SME Instrument funding for the same medtech concept — a signal that their technology passed rigorous European evaluation twice. Their positioning is highly specific: biocompatible polymer alternatives to metal trauma fixation hardware, a niche where material performance, regulatory compliance, and clinical adoption barriers all intersect. For a consortium needing a material innovator with demonstrated EU grant credibility and a focus on orthopaedic implants, they are a rare profile in the Israeli medtech landscape.

Highlights from their portfolio

• MP-ORIF
  Secured the full SME Instrument Phase 2 grant of EUR 1,161,785 — the larger and more competitive of the two EU SME funding phases — for developing a biocompatible polymer material intended to replace conventional metal fixation implants in orthopaedic trauma surgery.
• MP-ORIF
  The Phase 1 feasibility grant (2016, EUR 50,000) directly converted into a Phase 2 award, demonstrating that the technology concept survived independent expert evaluation and merited full development investment.